Lilly may extend grant disclosure policy globally

Share this article:
Eli Lilly said it is studying the feasibility of extending its grants disclosure policy globally and could do so by next year.

Publishing the data on worldwide education grants and charitable contributions would complement the Indianapolis drug firm's decision last May to publicize grants given to US organizations. Lilly posts the information on its educational grants portal on a quarterly basis.

Lilly CEO Sidney Taurel said the firm is “working hard to evaluate the legal, regulatory and other considerations” related to disclosing the information worldwide, targeting 2008 as a possible timeframe.

He made the statement in a letter to the group Essential Action, which is leading a broad coalition of public health and consumer organizations leaning on Big Pharma to disclose all of its charitable and educational grants and gifts. Arguing that such funding influences physician prescribing, the coalition said disclosure “doesn't cure this problem, but it is a start.”

So far, the only company set to follow Lilly onto the grant disclosure bandwagon is Pfizer. In April its Medical Education Policy Committee recommended the adoption of a policy on disclosure of educational grants. The company will begin reporting grants given to US organizations in 2008.

Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...